Omar Nadeem shared findings from the CAR-PRISM trial evaluating ciltacabtagene autoleucel in high-risk smoldering myeloma during the third Clinical Trials Plenary at #AACR26. Read the full recap in AACR Annual Meeting News: https://t.co/euYQYYGoKS https://t.co/epmDDd7uRC